Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help?

Shafiee, Mohamad Nasir; Khan, Gulafshana; Ariffin, Rina; Abu, Jafaru; Chapman, Caroline; Deen, Suha; Nunns, David; Barrett, David A.; Seedhouse, Claire; Atiomo, William

doi:10.1016/j.ygyno.2013.10.028

Cited by 62 publications

(43 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metformin can inhibit cell proliferation and induce apoptosis in endometrial cancer cell lines and it can exert chemopreventive effects in endometrial carcinogenesis (18)(19)(20)56).…”

Section: Biological Datamentioning

confidence: 99%

See 1 more Smart Citation

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

Gadducci

Biglia

Tana

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Metformin can inhibit cell proliferation and induce apoptosis in endometrial cancer cell lines and it can exert chemopreventive effects in endometrial carcinogenesis (18)(19)(20)56).…”

Section: Biological Datamentioning

confidence: 99%

“…Metformin has been also found to reduce the incidence and mortality of ovarian cancer (13)(14)(15)(16)(17), endometrial cancer (17)(18)(19)(20)(21), and breast cancer (17,22).…”

Section: Introductionmentioning

confidence: 99%

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

Gadducci

Biglia

Tana

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…The extensive experience of metformin use in women with PCOS suggests a potential role for this biguanide in the prevention and treatment of endometrial cancer in these patients [83]. Metformin is also associated with a significant improvement in the overall survival of diabetic patients with endometrial cancer [84].…”

Section: Medical Therapymentioning

confidence: 99%

Obesity and female malignancies

Benedetto

Salvagno

Canuto

et al. 2015

Best Practice & Research Clinical Obstetrics & Gynaecol

View full text Add to dashboard Cite

“…In recent years numerous studies have indicated that metformin could be effective in endometrial cancer risk reduction in PCOS patients in association with effective antiproliferative activity in endometrial hyperplasia, low grade endometrial carcinoma and even in endometrial serous carcinoma cell line (Perino et al, 1987a;1997b;Shen et al, 2008;Shen et al, 2008;Prat et al, 2009;Sarfstein et al, 2013;Shafiee et al, 2013). However clinicopathologic studies regard to metformin in restoring normal endometrial morphology or change to atrophic endometrium in compare with high dose progesterone are limited.…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative Effect of Metformin on the Endometrium - a Clinical Trial

Tabrizi¹,

Sayyah-Melli²,

Foroughi³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Unopposed estrogen has a central role in development of endometrial benign, premalignant and malignant lesions. The aim of this study was to evaluate the anti-estrogenic effect of metformin on endometrial histology in comparison with progesterone. Materials and Methods: A total of 43 patients who were referred to our center for abnormal uterine bleeding and had a histologic diagnosis were disordered proliferative endometrium or simple endometrial hyperplasia were included and randomly distributed in two groups treated with metformin (500mg Bid) or megestrol (40mg daily), respectively, for three months. After this period the patients were evaluated by another endometrial biopsy to assess the impact of the two drugs in restoring normal endometrial histology. Results: Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95.5%) while this positive response was achieved in only 13 out of 21 patients (61.9%) in the megstrol group. In addition two low grade endometrial carcinomas in the metformin group responded very well. Conclusions: We conclude that metformin could be used as an effective antiestrogenic agent in control of abnormal endometrial proliferative disorders.

show abstract

Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help?

Cited by 62 publications

References 48 publications

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning

Obesity and female malignancies

Antiproliferative Effect of Metformin on the Endometrium - a Clinical Trial

Contact Info

Product

Resources

About